objeCtives: Personalised medicine continues to be a hot topic in health care evaluation, particularly in diseases where response to therapy within the patient population is often heterogenous. The results of an analysis previously presented at ISPOR showed that the proportion of cancer trials investigating personalised medicine rose 7-fold between 2000 and 2010. However, in 2011, this trend appeared to have reached a plateau, with the proportion of cancer trials considering personalised medicine settling at around 15-20%. The aim of this study was to update the previous research to take account of the proportion of cancer trials which included personalised medicine between 2012 and 2013, inclusive, to assess whether this pattern has changed in more recent years. Methods: Terms including 'diagnostic', 'prognostic' and 'biomarker' were used to search ClinicalTrials. gov for all interventional cancer trials which started between 2012 and 2013 and considered the use of individualised medicine. These trials were then compared to those of all interventional cancer trials listed on ClinicalTrials. gov starting in the same period. Results: Of all cancer trials analysed between 2000 and 2013, inclusive, 3,664 of 25,203 (14.5%) considered personalised medicine. Although the previous analysis showed a substantial increase in this proportion between 2000 and 2010, this trend does not appear to continue into the current decade. The proportion of trials considering personalised medicine identified in this update was consistent with that seen in 2011, with 17.7% of trials in 2012 and 18.8% in 2013 considering personalised medicine, perhaps signifying a lack of further increase in research interest. ConClusions: Surprisingly, in spite of the apparent drive and enthusiasm for the use of personalised medicine within the medical community, these results indicate that the proportion of such trials may have reached a plateau. Therefore, this might suggest that cancer research is continuing to focus on traditional, non-personalised interventions. objeCtives: Women who undergo mastectomy, whether due to a first-time breast cancer diagnosis or recurrence, are often presented with the option of breast reconstruction. Decisions whether to undergo reconstruction are informed by women's surgery expectations, which develop based on many factors, including past knowledge and experience. The aim of this study was to examine the impact of previous breast cancer diagnosis on a women's approach to expectation-identification of their reconstructed breast appearance. Methods: This study was performed using crosssectional data as part of a larger field-test. Expectations scales of the BREAST-Q PRO were administered in a clinical setting to breast cancer patients seeking immediate breast reconstruction. Responses were categorized into specific (unlikely, somewhat likely, very likely) or vague expectations (don't know) as the dependent variable. The independent variable was defined as previous or primary diagnosis. Chi Square and one-way ANOVA were performed using SPSS22. Results: The study sample (n = 62; response rate, 66%) was characterized by a mean age of 49.6 ± 9.2 years, 82.3% married, 77.4% employed and 79.0% Caucasian. Twenty-three (37.1%) had a history of previous breast cancer diagnosis without mastectomy. Women who had previous breast cancer diagnosis were more likely to select a specific expectation in response to what their new breast (s) would look like in the mirror clothed (ETA squared; 0.11, P= 0.011) and unclothed (ETA squared; 0.09, P= 0.017) one year after reconstruction. ConClusions: Expectancies guide perception, so that people tend to focus on events that are congruent with their expectations. In our study, women undergoing breast reconstruction were more likely to identify a specific expectation about the appearance of their reconstructed breast if they had been previously diagnosed with breast cancer. More research is needed to determine additional factors that may mediate the development of preoperative surgical expectations. Such information will aid in facilitating patient-physician communication.
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NICe restrICtIveNess CoMPared to the Market authorIzatIoN IN oNCology aNd NoN-oNCology revIews objeCtives: To determine how often NICE recommendations are more restrictive than market authorizations in oncology reviews compared to non-oncology reviews. Methods: 161 NICE Technology Appraisal decisions from 2007-2013 were evaluated; 95 non-oncology and 66 oncology reviews. For each generic drug included in a review, the corresponding brand and market authorization was retrieved from the EMA or MHRA. NICE positive decisions were compared to the market authorizations. Any decision that included language that restricted the population eligible for treatment or reimbursement for a given therapy was categorized as "recommend with restrictions." NICE positive decisions that were not more restrictive than the market authorizations were categorized as "recommend." Negative decisions were categorized as "do not recommend." Results: Oncology reviews were more likely to By comparison, only 7/88 (8%) of NICE-approved cancer appraisals have been subject to restrictions in addition to the label. ConClusions: Access to anti-cancer drugs under the CDF tends to be more restrictive than those approved by NICE. Thus, attaining NICE approval for CDF-approved drugs could broaden clinical access as well as ensuring reimbursement after the fund is due to close in 2016. Nevertheless, the CDF does provide a formal mechanism under which reimbursement can be provided for off-label use of cancer drugs, which NICE will not consider. objeCtives: To compare drug prices and public expenditure of out-patient cancer drugs between two consecutive periods: reference based pricing (RBP) and public tendering at MoH in 2010 and RBP only in a positive drug list (PDL) at the National Health Insurance Fund (NHIF) in 2011. Methods: We compared the prices of the 40 products, which are used in out-patient setting. We used public documents like tender results from 2010 MoH tender and reimbursement list of NHIF in 2011. Results: 70% of the products (n= 28) were with higher prices, 20% had no price change (n= 8) and 10% (n= 4) had lower prices in 2011. In 2010, 15% (n= 6) had 50% lower prices than same products' prices in the PDL in 2011. For 10% of the products (n= 4) in 2010, after tendering, the MoH paid higher prices than the registered prices after RBP. These were patented products, without generic competition. In 2011, NHIF paid BGN 18.591.365 for these 40 drugs. For the same quantities, with MoH 2010 prices, the public expenditure could be BGN 10.788.430 (42% lower). ConClusions: Public tendering achieved lower prices than RBP alone. For patented products, without generic competition, tendering is not the ultimate solution. Tendering should be used with caution, as it can drive some producers out of the market and create non-competitive environment with counter-productive results. Frequent changes of the laws and regulations, without budget impact analysis, is like gambling. Longterm national drug pricing policy is hardly needed and should be strictly followed.
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PCN259 uNderstaNdINg CaregIver BurdeN IN ColoreCtal CaNCer: what role do PatIeNt aNd Carer faCtors Play?
Maguire R. 1 , Hanly P. 1 , Hyland P. 1 , Sharp L. 2 1 National College of Ireland, Dublin, Ireland, 2 National Cancer Registry Ireland, Cork, Ireland objeCtives: This study aimed to explore the key determinants of caregiver burden in colorectal cancer (CRC) carers. Specifically we analysed the effect of (i) patient health (ii) care-related activities, and (iii) carer characteristics, as predictors of four distinct aspects of carer burden. Methods: 495 CRC survivors (response rate = 39%) diagnosed 2007-2009 completed a questionnaire which collected information on socio-demographic characteristics, as well as disease and treatment-related factors. General health status was measured using the EORTC QLQ30.228 of these survivors indicated that they had informal carers who were then sent a questionnaire including questions on socio-demographic factors, health status and care-related costs as well as the Caregiver Reaction Assessment (CRA) scale. Hierarchical multiple regression analysis was used to assess the impact of patient factors, care-related activities and carer characteristics on four burden elements within the CRA (family support, finances, schedule, and health). Results: 153 carers completed the carer questionnaire and were included in the analysis with their corresponding patients. Patient characteristics and disease-related factors were the strongest predictor of all four aspects of caregiver burden ranging from 14% to 22% of explained variance. Care-related activities also significantly predicted burden scores (explaining an for 40% of decisions, were compared with those of three major HTA agencies: CADTH, NICE and PBAC. HTA reports and meeting transcripts were analysed and categorised by date, therapy area, decision, rationale, and pricing decision. Resubmissions or those not assessed by the western HTA agencies were excluded. Results: A total of 65 NHI reports were identified. Of these 26 reported decisions on oncology or cardiovascular drugs, 12 were excluded (3 resubmissions, 9 not reviewed by the other agencies). Prior to 2GNHI, 4 out of 5 decisions were positive, or 80% approval rate, while after, only 4 out of 9 were positive, a 44% approval rate. Prior to 2GNHI, all NHI reimbursement decisions identified (6) matched CADTH, NICE, and PBAC. After 2GNHI, only 6/9 or 66% matched. Clinical effectiveness and budget impact were most cited in reimbursement rejections. For example Zytiga, NHI appreciated the cost-effectiveness but stated budget impact was too high, issuing a negative recommendation, contrary to the other agencies. Interestingly, a 'local' product was recommended for limited reimbursement even though budget impact was high. ConClusions: Since implementation of Taiwan's NHI reforms in January 2013, cardiovascular and oncology drug approvals dropped by 36% and agreements with western agencies down 34%, placing an emphasis on budget impact. However, this analysis was constrained by its small sample size, and limited therapy areas. objeCtives: Since January 2009, NICE in the UK allows end of life (EOL) treatments to exceed the upper end (£30,000/QALY) of the threshold range for incremental cost-effectiveness ratios (ICERs) by using higher weights for EOL life-years. With discussions surrounding the concept and implementation, and the introduction of the value based assessment framework, the aim of this study was to review NICE technology appraisals (TAs) in oncology to assess the interpretation, implementation and implications of the criteria. Methods: All completed TAs in oncology since 2009 were searched. When multiple submissions of the same TA were made, the latest were selected. Data were extracted to capture details of the appraisal (e.g. treatment, indication and decision), the consideration of the five different EOL criteria (applicability, interpretation, effect on the decision) and the method of implementation (weighting, threshold). Results: 61 TAs, including six multiple technology appraisals, assessing 71 technologies were reviewed. EOL criteria were considered in 40 TAs covering 44 technologies. EOL weighting was considered appropriate for 36% of technologies. Most technologies fulfilled the criterion of < 24 month life expectancy (rejected in 14%), extension of life by ≥ 3 months or robustness of its calculation was the most common cause of rejection (32%/25% respectively). These criteria were inconsistently applied, using different methods (e.g. medians, restricted means from extrapolation, means from trial or model). The criterion of small population favoured technologies with limited indication (rejection 20%). Earlier TAs presented weight calculations, while later TAs only presented ICERs. ConClusions: Although aiming for greater transparency, the criteria left a large scope for interpretation in the decision making. Also, with the emphasis from applying higher weights to EOL life-years shifting to a differential threshold for certain indications, the original idea of considering wider societal preferences seem to have been neglected, that the new guidance should remedy. be issued a "do not recommend" decision than non-oncology reviews (56% vs. 16%, p< . 001). Over time, there was no significant trend in rates of "do not recommend" decisions for non-oncology reviews and oncology reviews, though rates of "do not recommend" decisions have increased for oncology reviews since 2008. There were no differences in the rates of "recommend" and "recommend with restriction" decisions between oncology and non-oncology reviews (p= . 87). Over time there was a significant decrease in the rates of "recommend with restrictions" decisions for oncology reviews (p= . 07), but no statistical trend in non-oncology reviews. ConClusions: NICE was more likely to issue a "do not recommend" decision for oncology reviews than for non-oncology reviews, but there was no difference in the overall rates of "recommend with restrictions" decisions. Over time, NICE appears to be replacing "recommend with restriction" decisions with "do not recommend" decisions in oncology reviews, but this did not pass traditional significance levels. We also performed manual search. We selected partial and full economic evaluation studies in cancerology, where at least one of the authors was affiliated to a Brazilian institution. Two authors performed study selection and data extraction independently. Disagreements were resolved through discussion or through consultation with a third reviewer. The study characteristics were summarized in figures and summary tables. Results: A total of 11946 records were identified. Fifty six articles met inclusion criteria, of these, 33 (59%) were a full and 23 (41%) were a partial economic evaluation. The cost-effectiveness analysis was the most used (27%). There was an increase in the number of publications over the years, especially after 2006. Researchers from the Southeast region of Brazil were responsible for the majority of the publications (82%). Cancers most frequently studied were breast cancer (37%), followed by cervical cancer (16%), lung cancer (12%) and colorectal cancer (9.0%). The technologies most studied were medications (34%). ConClusions: The expansion of the economic analysis literature could be explained by the growing demand for HTA studies by the National Policy for Health Technology Assessment in Brazil that may have stimulated the scientific production in this area. objeCtives: Crizotinib (Xalkori®) was approved for the treatment of adults with non-small cell lung cancer (NSCLC). The objective of this study was to illustrate the divergence of Health Technology Assessments in oncology by comparing the decisions of the National Institute for Health and Care Excellence (NICE), the Federal Joint Committee (G-BA) and French National Authority for Health (HAS). Methods: Crizotinib's pivotal trial (Study 1007) was analysed. NICE, G-BA and HAS reports were reviewed, decisions' drivers identified and final decisions compared. Results: Study 1007 was a randomised open-label trial comparing crizotinib with chemotherapy in patients with ALK+ advanced NSCLC and who had failed one chemotherapy regimen. The primary endpoint was progression-free survival (PFS) and overall survival (OS) was a secondary endpoint. While treatment with crizotinib increased significantly the PFS (4.7 months) no significant improvement in OS was observed versus chemotherapy group (OS interim analysis). Some quality of life (QoL) items (e.g. chest pain, dyspnea, fatigue) were improved within the crizotinib group. Even though no improvement in the OS was shown, the G-BA assessed the crizotinib benefit as considerable based on the improvement of QoL and morbidity decrease. The HAS also granted crizotinib an improvement in actual benefit of III based on the improvements in the PFS and QoL. However, the significant gain in PFS was not sufficient to get positive guidance from NICE. Indeed, NICE did not recommend the use of crizotinib due to the uncertainties surrounding the OS: interim OS data and high rate of patients "crossing-over" from standard therapy to crizotinib arm. ConClusions: Cross-over has become a real obstacle to appreciate oncology product value. While an additional benefit can be granted based on improvement in PFS plus morbidity and QoL results in Germany and France, products supported solely by an increased PFS and no change in OS may face access barriers in England. objeCtives: Taiwan is considered a challenging market to access, largely due to strict pricing and reimbursement policies. To assess the impact of health insurance reforms introduced in January 2013 (Second Generation National Health Insurance or 2GNHI), Taiwan reimbursement decisions and granted prices before and after the introduction were compared with major western countries. Methods: Publications of Taiwan NHI from March 2011 to February 2014 were searched and reimbursement decisions identified. The largest therapy areas, oncology and cardiovascular, which accounted
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